Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: A gynecologic oncology group study

Gynecologic Oncology

Volumn 67, Issue 3, 1997, Pages 255-258

  Look, Katherine Y ^a   Blessing, John A ^b   Valea, Fidel A ^c   McGehee, Ramon ^d   Manetta, Alberto ^e   Webster, Kenneth D ^f   Andersen, Willie A ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

EID: 0031469946     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4886     Document Type: Article

References (21)

1. 1. Davis JR, Moon LB: Increased incidence of adenocarcinoma of the uterine cervix. Obstet Gynecol 45:79-83, 1975
2. 2. Berkowitz RS, Ehrman RL, Lavizzo-Mourey R, Knapp RC: Invasive cervical carcinoma in young women. Gynecol Oncol 8:311-316, 1979
3. 3. Messing MJ, Gallup DG: Adenocarcinoma of the Cervix Clinical Features and Management, in Rubin SC, Hoskins W, (eds): Cervical Cancer and Preinvasive Neoplasia. Lippincott Raven, Philadelphia, p 263, 1996
4. 4. Hopkins MP, Morley GW: A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 77: 912-917, 1991
5. 5. Eifel PJ, Burke TW, Morris M, Smith T: Adenocarcinoma as an independent risk factor for recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59:38-44, 1995
6. 6. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L: Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases treated at the MD Anderson Cancer Center between 1965 and 1985. Cancer 65:2507-2514, 1990
7. 7. Bonomi P, Blessing J, Stehman FB, DiSaia PJ, Walton L, Major FJ: Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 3:1079-1085, 1985
8. 8. Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY: Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 168:805-807, 1993
9. 9. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group Study. J Clin Oncol 14:792-795, 1996
10. 10. Omura GA, Blessing JA, Vacarello L, Berman ML, Clarke-Pearson DL, Mutch D, Anderson B: Randomized trial of cisplatin versus cisplatin plus mitolactol (dibromodulcitol) versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15:165-171, 1997
11. 11. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vanderbulcke JM, Misset JL, Schwarzenberg L, Fourtillan JB: Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685-696, 1986
12. 12. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstener JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA: Biochemical modulation of fluorouracil efficacy in advanced colorectal cancer. J Clin Oncol 9:1067-1972, 1991
13. 13. Look KY, Muss HB, Blessing JA, Morris M: A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol (CCT) 18(1):19-22, 1995
14. 14. Look KY, Blessing J, Gallup DG, Lentz SS: A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol (CCT) 19(5):439-441, 1996
15. 15. Blessing JA: Design, Analysis and Interpretation of Chemotherapy Trials in Gynecologic Cancer, in Deppe G. (ed): Chemotherapy of Gynecologic Cancer 2nd ed, AR Liss, New York, pp 63-97, 1990
16. 16. Zaniboni A: Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 15:2432-2441, 1997
17. 17. Chu E, Voeller D, Koeller DM, Drake JC, Takimoto CH, Maley GF, Maley F, Allegra CJ: Identification of a RNA binding site for human thymidylate synthase. Proc Natl Acad Science USA 90:517-521, 1993
18. 18. Schwartz EL, Baptiste N, O'Connor CJ, Wadler S, Otter BA: Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res 54:1472-1478, 1994
19. 19. Houghton JA, Morton CL, Adkins DA, Rahman A: Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-α2a in colon carcinoma cells. Cancer Res 53:4243-4250, 1993
20. 20. Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg SM, Arbuck SG, Beveridge RA, Kales AN, Miller JA: Phase II study of fluorouracil, leucovorin and Interferon alpha-2a in metastatic colorectal carcinoma. J Clin Oncol 11:1737-1745, 1993
21. 21. Seymour MT, Slevin ML, Kerr DJ, Sunningham D, James RD, Ledermann JA, Perren TJ, McAdam WA, Harper PG, Stenning SP, Taylor I: Randomized trial assessing the addition of Interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 14:2280-2288, 1996